Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/148041
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fernández Dueñas, Víctor | - |
dc.contributor.author | Pérez Arévalo, Andrea | - |
dc.contributor.author | Altafaj, Xavier | - |
dc.contributor.author | Ferré, Sergi | - |
dc.contributor.author | Ciruela Alférez, Francisco | - |
dc.date.accessioned | 2020-01-16T14:30:09Z | - |
dc.date.available | 2020-01-16T14:30:09Z | - |
dc.date.issued | 2017-11-22 | - |
dc.identifier.issn | 1662-4548 | - |
dc.identifier.uri | http://hdl.handle.net/2445/148041 | - |
dc.description.abstract | Parkinson's disease (PD) is a progressive, neurodegenerative disorder that affects ~1% of individuals over the age of 60, which turns to 5% in subjects up to 85 years (de Lau and Breteler, 2006). On the other hand, a form of PD, called early-onset PD (EOPD), arises at an earlier age (<45; Bonifati et al., 2005; Ylikotila et al., 2015). EOPD patients generally display a slower progression of the disease and present a better response to dopaminergic treatments; however, they may finally develop a full PD symptomatology (i.e., bradykinesia, resting tremor, muscular rigidity and postural instability, drug-induced dyskinesia; Olgiati et al., 2016). | - |
dc.format.extent | 4 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fnins.2017.00652 | - |
dc.relation.ispartof | Frontiers in Neuroscience, 2017, vol. 11, num. 652 | - |
dc.relation.uri | https://doi.org/10.3389/fnins.2017.00652 | - |
dc.rights | cc-by (c) Fernández Dueñas, Víctor et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Malaltia de Parkinson | - |
dc.subject.classification | Oligòmers | - |
dc.subject.classification | Adenosina | - |
dc.subject.other | Parkinson's disease | - |
dc.subject.other | Oligomers | - |
dc.subject.other | Adenosine | - |
dc.title | Adenosine A1-A2A Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 682709 | - |
dc.date.updated | 2020-01-16T14:30:09Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 29213228 | - |
Appears in Collections: | Articles publicats en revistes (Institut de Neurociències (UBNeuro)) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Patologia i Terapèutica Experimental) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
682709.pdf | 723.14 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License